Community-acquired pneumonia primary prevention: Difference between revisions
m Bot: Removing from Primary care |
|||
(10 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
==Vaccination== | ==Vaccination== | ||
{| style="border: 0px; font-size: 85%; margin: 3px; width: | {| style="border: 0px; font-size: 85%; margin: 3px; width:80%;" align=center | ||
|valign=top| | |valign=top| | ||
|+ | |+ | ||
Line 18: | Line 18: | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Pneumococcal Vaccine | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Pneumococcal Vaccine | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Intramuscular injection | | style="padding: 5px 5px; background: #F5F5F5;" |Intramuscular injection | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Pneumococcal | | style="padding: 5px 5px; background: #F5F5F5;" |Pneumococcal conjugate vaccine (PCV13) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |All | | style="padding: 5px 5px; background: #F5F5F5;" |All adults 65 years of age or older should receive a dose of PCV13 followed by a dose of PPSV23 6 to 12 months later | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Chronic | *CSF leaks | ||
* | *Cochlear implants | ||
* | *Sickle cell disease/other hemoglobinopathies | ||
* | *Congenital or acquired asplenia | ||
* | *Congenital or acquired immunodeficiencies | ||
* | *HIV infection | ||
* | *Chronic renal failure | ||
* | *Nephrotic syndrome | ||
| style="padding: 5px 5px; background: #F5F5F5;" | One-time revaccination | *Leukemia | ||
* | *Lymphoma | ||
* | *Hodgkin disease | ||
* | *Generalized malignancy | ||
*Iatrogenic immunosuppression‡ | |||
*Solid organ transplant | |||
*Multiple myeloma | |||
| style="padding: 5px 5px; background: #F5F5F5;" | No revaccination | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Pneumococcal Vaccine | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Intramuscular injection | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Pneumococcal polysaccharide vaccine (PPSV23) | |||
| style="padding: 5px 5px; background: #F5F5F5;" |All persons > 65 years of age, 6-12 months before or after PCV13 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Chronic heart disease | |||
*Chronic lung disease | |||
*Diabetes mellitus | |||
*CSF leaks | |||
*Cochlear implants | |||
*Alcoholism | |||
*Chronic liver disease | |||
*Cigarette smoking | |||
*Sickle cell disease/other hemoglobinopathies | |||
*Congenital or acquired asplenia | |||
*Congenital or acquired immunodeficiencies | |||
*HIV infection | |||
*Chronic renal failure | |||
*Nephrotic syndrome | |||
*Leukemia | |||
*Lymphoma | |||
*Hodgkin disease | |||
*Generalized malignancy | |||
*Iatrogenic immunosuppression | |||
*Solid organ transplant | |||
*Multiple myeloma | |||
| style="padding: 5px 5px; background: #F5F5F5;" | One-time revaccination, 5 years after first dose in the following patients: | |||
*Sickle cell disease/other hemoglobinopathies | |||
*Congenital or acquired asplenia | |||
*Congenital or acquired immunodeficiencies | |||
*HIV infection | |||
*Chronic renal failure | |||
*Nephrotic syndrome | |||
*Leukemia | |||
*Lymphoma | |||
*Hodgkin disease | |||
*Generalized malignancy | |||
*Iatrogenic immunosuppression | |||
*Solid organ transplant | |||
*Multiple myeloma | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Inactivated Influenza Vaccine | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Inactivated Influenza Vaccine | ||
Line 48: | Line 94: | ||
*[[Pregnancy]] | *[[Pregnancy]] | ||
*[[Aspirin]] therapy in persons < 18 years of age | *[[Aspirin]] therapy in persons < 18 years of age | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Annually | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Live Attenuated Influenza Vaccine | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | Live Attenuated Influenza Vaccine | ||
Line 55: | Line 101: | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Healthy persons 5–49 years of age,a including health care providers and household contacts of high-risk persons | | style="padding: 5px 5px; background: #F5F5F5;" |Healthy persons 5–49 years of age,a including health care providers and household contacts of high-risk persons | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Avoid in high-risk persons | | style="padding: 5px 5px; background: #F5F5F5;" |Avoid in high-risk persons | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Annually | ||
|- | |- | ||
| style="padding: 0px 5px; background: #F5F5F5;" colspan=5|<small> Adapted from IDSA/ATS Consensus Guidelines on the Vaccine Prevention for Community-Acquired Pneumonia in Adults. <ref name="pmid17278083">{{cite journal |author=Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG |title=Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults |journal=[[Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America]] |volume=44 Suppl 2 |issue= |pages=S27–72 |year=2007 |month=March |pmid=17278083 |doi=10.1086/511159 |url=http://www.cid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17278083 |accessdate=2012-09-06}}</ref> </small> | | style="padding: 0px 5px; background: #F5F5F5;" colspan=5|<small> Adapted from IDSA/ATS Consensus Guidelines on the Vaccine Prevention for Community-Acquired Pneumonia in Adults. <ref name="pmid17278083">{{cite journal |author=Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG |title=Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults |journal=[[Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America]] |volume=44 Suppl 2 |issue= |pages=S27–72 |year=2007 |month=March |pmid=17278083 |doi=10.1086/511159 |url=http://www.cid.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17278083 |accessdate=2012-09-06}}</ref> </small> | ||
Line 62: | Line 108: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Pneumonia]] | [[Category:Pneumonia]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
Latest revision as of 21:02, 29 July 2020
Community-Acquired Pneumonia Microchapters |
Differentiating Community-acquired pneumonia from other Diseases |
Diagnosis |
Treatment |
Case Studies |
Community-acquired pneumonia primary prevention On the Web |
American Roentgen Ray Society Images of Community-acquired pneumonia primary prevention |
Directions to Hospitals Treating Community-acquired pneumonia |
Risk calculators and risk factors for Community-acquired pneumonia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
There are several ways to prevent infectious pneumonia. Appropriately treating underlying illnesses (such as AIDS), smoking cessation, vaccination against pneumococcal and influenza are the commonly used methods.
Vaccination
Vaccine | Route of Administration | Type of Vaccine | Recommended Groups | Specific high-risk indications for vaccination | Re-vaccination schedule |
---|---|---|---|---|---|
Pneumococcal Vaccine | Intramuscular injection | Pneumococcal conjugate vaccine (PCV13) | All adults 65 years of age or older should receive a dose of PCV13 followed by a dose of PPSV23 6 to 12 months later |
|
No revaccination |
Pneumococcal Vaccine | Intramuscular injection | Pneumococcal polysaccharide vaccine (PPSV23) | All persons > 65 years of age, 6-12 months before or after PCV13 |
|
One-time revaccination, 5 years after first dose in the following patients:
|
Inactivated Influenza Vaccine | Intramuscular injection | Killed virus | All persons > 50 years of age, High-risk persons 6 months–49 years of age, household contacts of high-risk
persons, health care providers, children 6–23 months of age |
|
Annually |
Live Attenuated Influenza Vaccine | Intranasal spray | Live virus | Healthy persons 5–49 years of age,a including health care providers and household contacts of high-risk persons | Avoid in high-risk persons | Annually |
Adapted from IDSA/ATS Consensus Guidelines on the Vaccine Prevention for Community-Acquired Pneumonia in Adults. [1] |
References
- ↑ Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG (2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 44 Suppl 2: S27–72. doi:10.1086/511159. PMID 17278083. Retrieved 2012-09-06. Unknown parameter
|month=
ignored (help)